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Abstract
The burgeoning evidence of patients diagnosed with sigmoidal hypertrophic cardiomyopathy 
(HCM) later in life has revived the quest for distinctive features that may help discriminate it from 
more benign forms of isolated septal hypertrophy often labelled ventricular septal bulge (VSB). 
HCM is diagnosed less frequently than VSB at older ages, with a reversed female predominance. 
Most patients diagnosed with HCM at older ages suffer from hypertension, similar to those with 
VSB. A positive family history of HCM and/or sudden cardiac death and the presence of 
exertional symptoms usually support HCM, though they are less likely in older patients with 
HCM, and poorly investigated in individuals with VSB. A more severe hypertrophy and the 
presence of left ventricular outflow obstruction are considered diagnostic of HCM, though stress 
echocardiography has not been consistently used in VSB. Mitral annulus calcification is very 
prevalent in both conditions, whereas a restrictive filling pattern is found in a minority of older 
patients with HCM. Genetic testing has low applicability in this differential diagnosis at the 
current time, given that a causative mutation is found in less than 10% of elderly patients with 
suspected HCM. Emerging imaging modalities that allow non-invasive detection of myocardial 
fibrosis and disarray may help, but have not been fully investigated. Nonetheless, there remains a 
considerable morphological overlap between the two conditions. Comprehensive studies, 
particularly imaging based, are warranted to offer a more evidence-based approach to elderly 
patients with focal septal thickening.
INTRODUCTION
An isolated hypertrophy of the basal segment of the interventricular septum protruding into 
the outflow tract of the left ventricle (LV), named ventricular septal bulge (VSB),1–3 is fairly 
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common in elderly individuals, and may be difficult to distinguish from genetic hypertrophic 
cardiomyopathy (HCM).245 The matter has been recently reconsidered because of an 
increasing number of reports demonstrating that some HCM variants may have late onset in 
middle age and elderly individuals, and are compatible with normal longevity.6–8 The 
widespread availability of non-invasive cardiac imaging modalities, particularly 
transthoracic echocardiography, has significantly contributed to this trend.79 Coincident with 
these medical developments, patients are increasingly exposed to information from the 
media on sudden unexpected deaths due to HCM. Because of potential life-threatening 
complications associated with a diagnosis of HCM, the notion that isolated septal 
hypertrophy should be considered as ‘normal for age’ has been called into question.
As the number of older patients coming to cardiology services increases, and the use of 
cardiac imaging expands, distinguishing between HCM and VSB in elderly individuals will 
become more of an issue in the years to come. This review provides readers with a 
comprehensive and updated summary of the evidence available on differential diagnosis 
between HCM and VSB in the elderly. Empirically, we will start with the assumption that 
the two conditions are different, and will review and discuss data in support or against this 
hypothesis. Initial definitions, search strategy and selection criteria are summarised in box 1. 
Selected clinical and instrumental features in HCM versus VSB are discussed in the next 
paragraphs, and summarised in table 1. A practical differential diagnostic algorithm is 
proposed in the last paragraph.
DEMOGRAPHICS AND MEDICAL HISTORY
Elderly
Epidemiology of HCM is little known, and an unexplained increase in LV thickness is 
reported in a wide range (0.02%–0.23%) of the general adult population.1011 No systematic 
data are available on the number of individuals diagnosed with HCM after the age of 60 
years as compared with younger ages. They accounted for about 30% in a series of 277 
patients with HCM,6 though this is probably an underestimate of the true prevalence.781819 
On the contrary, it is widely recognised that the prevalence of VSB increases with age,11415 
ranging from 4% to 8% in individuals ≥60 years of age and reaching 10% in the eighth 
decade of life.11415 Thus, VSB seems to be diagnosed more frequently than HCM at older 
ages.
Sex
Patients with VSB did not display a sex preference,11415 in contrast to HCM, which has 
been generally characterised by a 3:2 male predominance,6 at least at younger ages.2021 A 
recent review of 969 consecutive American and Italian patients with HCM demonstrated a 
reversed 60% versus 30% female predominance only in patients older than 60 years of age.
22 This prevalence may however be driven by the well-known increased survival of females 
relative to males in older age groups. Thus, a clear gender difference in prevalence of HCM 
and VSB at older ages has yet to be established.
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Family history is frequently disregarded during medical interview in elderly patients. A 
positive family history of HCM and/or sudden cardiac death (SCD), particularly in first-
degree relatives, represents a very important piece of information to support a diagnosis of 
HCM.1011 Nonetheless, several works have shown that a positive family history of 
HCM/SCD is significantly less common in older than in younger patients with HCM, with a 
prevalence of approximately 10%–20% in the former group.7923 This decreased prevalence 
is likely due to the absence of a clear genetic background in HCM of the elderly (see 
genetics below).
Family history of HCM/SCD has been poorly investigated in VSB studies, and found in 
none of the 240 individuals diagnosed with VSB after a retrospective review of 4104 
ambulatory echocardiograms.14 Thus, available data weakly suggest that a positive family 
history of HCM/SCD can help confirming HCM and excluding VSB in elderly patients.
Hypertension
A history of hypertension has been frequently regarded as an exclusion criterion for HCM.24 
However, prevalence of hypertension dramatically increases with advancing age, to the point 
where more than half of people ≥60 years are affected. Thus, a history of hypertension can 
no longer be considered tout court as an exclusion criterion for HCM when dealing with 
elderly patients. Indeed, in contemporary adult HCM populations, prevalence of 
hypertension ranges from 20% to 60%.20212325–29 The prevalence of hypertension in VSB 
observational studies ranges between 50% and 80%,11415 thus slightly higher than that 
reported in HCM studies. However, considering that a conclusive independent association 
between hypertension and VSB has yet to be confirmed,114–16 a history of hypertension is 
currently of little help in differentiating VSB from HCM.
SYMPTOMS AND PHYSICAL EXAMINATION
Symptoms
HCM in the elderly may be frequently misdiagnosed, because symptoms such as dyspnoea, 
chest pain, palpitations and syncope are more commonly attributed to other cardiac disorders 
such as coronary disease, valvular heart disease and atrial fibrillation. In general, elderly 
patients with HCM do present with exertional symptoms.67930 On the contrary, the majority 
of VSB studies are retrospective in nature, where patients had been selected based on 
echocardiographic criteria and not because of their symptoms.11415 Few case reports of 
symptomatic patients with VSB have been published in the literature.412 Importantly, 
patients with HCM but not with VSB are routinely referred to exercise testing for prognostic 
stratification, where symptoms can be uncovered. The usefulness of stress testing in patients 
with VSB, although somehow suggested by the European guidelines,10 has never been 
prospectively investigated.
Physical examination
Physical examination is often normal both in HCM and VSB, though an ejection systolic 
murmur due to dynamic left ventricular outflow tract (LVOT) obstruction may be 
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appreciated, and modified by manoeuvres that increase or reduce ventricular preload or 
afterload. This finding may help differentiate obstructive HCM from aortic stenosis,10 but it 
has not been used for HCM versus VSB, and it has been described only in few contemporary 
HCM and VSB case reports.812
ELECTROCARDIOGRAPHY
Rest ECG
A 12-lead rest ECG is recommended in the initial evaluation of patients with HCM, and as a 
screening tool for first-degree relatives of patients with HCM.1011 ECG is a sensitive but 
nonspecific marker of left ventricular hypertrophy (LVH), because it is unable to distinguish 
among HCM, VSB, hypertension and aortic stenosis. LVH by ECG is found in about 60%–
70% of patients with HCM,29–31 whereas data are sparse in patients diagnosed with VSB.45 
The largest study to date found LVH at ECG in only 12% of patients with VSB. Thus, LVH 
by ECG appears more prevalent in elderly individuals with HCM than those with VSB, but 
provides little help with differential diagnosis.
Ambulatory ECG
ECG monitoring is not requested for HCM diagnosis, but recommended for risk 
stratification of SCD (ie, ventricular tachycardia) and stroke (ie, atrial fibrillation).1011 
American HCM guidelines underline that the frequency of arrhythmias detected during 
ambulatory ECG monitoring is age related;10 however, no specific data exist on the 
prevalence of atrial and ventricular arrhythmias in elderly patients with HCM. No published 
data on ambulatory ECG monitoring in patients with VSB are available.
ECHOCARDIOGRAPHY
LV shape and patterns of hypertrophy
LVH is the main echocardiographic feature of HCM. However, the distribution of 
hypertrophy within the LV walls and segments may significantly differ from one patient with 
HCM to another, and different patterns of LVH have been described 32 (figure 2). In general, 
HCM affects the interventricular septum more than other LV walls, and asymmetric septal 
hypertrophy (classically defined by a ratio between the septal and posterior wall diastolic 
thickness ≥1.3–1.5) has been considered as a key diagnostic feature to distinguish between 
HCM and LVH secondary to hypertension, which is generally symmetrical.21 In addition, 
some patients with HCM exhibit asymmetric septal hypertrophy and a greater thickness of 
the basal as compared with the mid-distal portion of the septum, lending the characteristic 
sigmoidal septal shape (figure 2). Numerous studies confirmed a predominance of sigmoidal 
HCM among the elderly.253334 Experts recently estimated that almost half of the patients 
diagnosed with HCM have a sigmoidal pattern of LVH.32
Patients with VSB have also been usually characterised by an asymmetric septal 
hypertrophy particularly isolated to the upper segment (ie, with a proximal-to-mid/distal 
septal thickness ratio ≥1.3–1.5) (figures 1 and 3). Some Authors included subjects with 
sigmoid-shaped septum without hypertrophy,15 but most VSB cohorts comprised only 
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individuals with a proximal septal wall thickness >12–13 mm,12131416 applying the same 
entry criterion used in contemporary HCM cohorts.2021 Thus, a considerable overlap exists 
between the two conditions. Nonetheless, patients with HCM generally display greater 
thickness of both the interventricular septum (frequently >15 mm) and the posterior wall 
(frequently >11 mm) than patients with VSB 216 (figure 3). Normal posterior wall 
thicknesses (ie, <11 mm) have been generally reported in VSB studies 11415 as compared 
with HCM studies in the elderlies, in which some degree of hypertrophy was also involving 
the posterior wall.252930 Thus, a less severe degree of hypertrophy and a normal posterior 
wall thickness may potentially help differentiate between patients with VSB and elderly 
patients with HCM.
Aortoseptal angle
A sigmoid-shaped septum has been consistently associated with a sharper angulation 
between the long axes of the LV and the aorta (figure 3). Studies generally found an 
aortoseptal angle <110° in patients with VSB.2312 It has been hypothesised that the age-
related dilation and lengthening of the aorta might push the septum downward and kink its 
upper portion,3 and that a sharper angle may favour a Venturi mechanism for the generation 
of LVOT obstruction.2 However, no association was found between the aortoseptal angle and 
LVOT obstruction at rest in a recent study of 240 patients with VSB.14 On the contrary, an 
aortoseptal angle ≤100° had a 27% sensitivity and 91% specificity for predicting provocable 
LVOT obstruction in a population of 160 patients with non-obstructive HCM.35 
Measurement of the aortoseptal angle by echocardiography is highly dependent on the 
position of the transducer and consequently poorly reproducible. Better and more 
standardised aortoseptal angle estimates may be obtained by cardiovascular MR (CMR), and 
one CMR study of 153 patients with HCM confirmed that a sharper aortoseptal angle was 
associated with dynamic LVOT obstruction.27 Notably, the intraobserver and interobserver 
concordance was very high in this study (0.91 and 0.88, respectively), suggesting that CMR 
may be the optimal technique for measuring the aortoseptal angle in future HCM and VSB 
studies.
Mitral annulus calcification
Mitral annulus calcification (MAC) occurs with ageing. Unfortunately, no standard method 
of quantification of MAC exists, and both echocardiography (figure 3) and X-ray-based 
imaging modalities have been used to screen for the presence and severity of MAC. MAC 
has been demonstrated in about 30%–70% of elderly subjects with both HCM 9252931 and 
VSB.1415 Some studies also suggested a higher prevalence of MAC when hypertension was 
associated.1429 While MAC may simply represents an age-related phenomenon, conditions 
that elevate LV filling pressure such as HCM increase stress on the mitral apparatus, thus 
likely accelerating the development of MAC. However, the significance of MAC in HCM 
has been poorly investigated. Some authors suggested a contribution of MAC to LVOT 
obstruction in elderly patients with HCM,30 which has also been acknowledged in recent 
European guidelines.10
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LVOT obstruction is a hallmark of HCM, and patients with HCM are currently classified 
based on the presence or absence of LVOT obstruction either at rest or under stress 
conditions. LVOT pressure gradients are routinely measured by echocardiography at rest and 
after physical exercise, Valsalva manoeuvre or amyl nitrite administration.1011 Systolic 
anterior movement of the mitral valve (SAM) and mitral-septal contact is believed to be 
responsible for LVOT obstruction in the majority of cases 36 (figure 3). Available evidence 
suggests a comparable 50%–70% prevalence of LVOT obstruction and SAM in younger and 
elderly patients with HCM.7923252931 LVOT obstruction is considered an important 
supportive diagnostic criterion for HCM, to the point that in one study patients initially 
classified as VSB were assigned a diagnosis of HCM after the demonstration of LVOT 
obstruction.14 On the contrary, patients with VSB do not usually present with LVOT 
obstruction, at least at rest.1515 Although European guidelines state that stress 
echocardiography should be routinely considered in symptomatic patients with VSB in the 
same way as in patient with unequivocal HCM,10 this recommendation does not reflect the 
common clinical practice, and the differential diagnostic role of stress echocardiography in 
patients with VSB has yet to be established in prospective studies.
LV diastolic and systolic function
With ageing, the human heart becomes thicker and stiffer and develops progressive LV 
diastolic dysfunction, characterised by progressive increase in LV filling pressure and, with 
time, an enlargement of the left atrium. In patients with HCM, these pathological changes 
progress in a more expedited fashion and usually in the contest of a preserved or increased 
global systolic function.10 Current guidelines recommend a multiparametric evaluation of 
LV diastolic function, which includes the estimation of E/A ratio from mitral diastolic 
Doppler inflow, E/E′ ratio using tissue-Doppler derived early mitral annulus velocity (E′) 
and left atrial dimensions (figure 3). In patients with HCM, a restrictive LV filling pattern 
(characterised by a E/A ratio ≥2, a E/E′ ratio ≥14 and a left atrial volume ≥34 mL/m2) is 
frequently encountered,10 even at very old ages.9 This is probably less evident in subjects 
diagnosed with a VSB, and one study comparing age-matched and gender-matched patients 
with VSB and HCM found significantly higher E/E′ ratio and left atrial dimension in the 
latter group.16 These are to date the only few data available suggesting a worse diastolic 
function in HCM versus VSB.
Measurements of subtle LV systolic dysfunction by speckle tracking echocardiography may 
help differentiating between HCM and other forms of LVH,37 including VSB. Patients with 
HCM have abnormalities in regional and global systolic longitudinal strain that are related to 
the site and degree of abnormal myocardial hypertrophy.38 In particular, patients with 
sigmoidal HCM have more abnormal strain in the proximal septum than in other LV 
segments.39 Further studies are needed to evaluate the diagnostic utility of these 
measurements in elderly patients with unspecified isolated proximal septal hypertrophy.
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Developments in CMR technology and its increasing availability in many healthcare settings 
have led to a substantially greater role of this technique in the morphological 
characterisation and risk stratification of patients diagnosed with HCM.10 However, its 
application has been limited in elderly patients with HCM, and none in patients with VSB. 
Therefore, only few concepts will be reported in the following paragraphs.
LV mass and LVH pattern
Quantification of LV mass with CMR is superior to echocardiography,26 particularly in the 
setting of asymmetric LVH,40 where conventional echocardiographic formulas assuming an 
ellipsoid geometry of the LV have clear limitations, and should probably be avoided (figure 
2). LV mass in patients with hypertrophy confined only to a few segments in the LV wall, 
such as the elderly with sigmoidal HCM, may be within normal ranges even in the presence 
of clinically significant disease.2641 Thus, increased LV mass is not a requirement for 
establishing a clinical diagnosis of HCM, and this parameter should not be used to 
distinguish between HCM and other asymmetric form of LVH associated with ageing, 
particularly a VSB.
Mitral valve abnormalities
CMR may be superior to echocardiography also in the evaluation of morphological and 
functional mitral valve abnormalities, which may lead to LVOT obstruction in patients with 
HCM.42 In particular, CMR may allow superior evaluation of mitral valve leaflet length and 
number, and insertion sites of the papillary muscles. These findings are increasingly reported 
in patients with HCM, 43 and may support a diagnosis of HCM as opposed to VSB.
Late gadolinium enhancement
Late gadolinium enhancement allows visualisation and quantification of fibrotic areas within 
the myocardium. The pattern of mid-wall patchy fibrosis in hypertrophied segments of the 
myocardium, which is typical of HCM, is present in about 65% of patients with HCM, and 
may be of help in differentiating true HCM from other conditions,44 including the VSB. 
However, no CMR study has yet explored this possibility. In addition, a much lower 
frequency of late gadolinium enhancement (37%) has been reported in patients with a late 
diagnosis of HCM,7 thus questioning its utility in the differential diagnosis of HCM in 
elderly patients, and the effective existence of two separate clinical entities.
CORONARY ANGIOGRAPHY
Coronary angiography is recommended as a diagnostic tool in patients with suspected HCM 
and typical exertional chest pain.1011 Prevalence of coronary artery disease (CAD) ranged 
from 0% to 40% in retrospective HCM studies of elderly patients, and very few data are 
available in VSB studies,14 which in most cases enrolled asymptomatic patients who did not 
undergo coronary angiography.115 Nonetheless, no independent association has been shown 
between CAD and either sigmoidal HCM or VSB. Intriguingly, however, a recent study of 
5128 patients with CAD found that those who had asymmetric septal hypertrophy (5.8%) 
were significantly older and had a significantly higher frequency of obstructive CAD of the 
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right and the left circumflex coronary arteries.45 This finding suggests that myocardial 
ischaemia due to CAD, particularly when involving arteries that supply the basal 
interventricular wall, may somehow contribute to the pathogenesis of VSB in the elderly, 
and perhaps to the sigmoidal pattern of LVH found in elderly HCM.
GENETICS
HCM is the most common autosomal dominant monogenic cardiac disease, but it has 
variable and age-related penetrance and may be due to de novo mutations absent in parents.
3246 Although several commercial genetic panels are available, the clinical use of genetic 
testing is limited, because of the vast genetic heterogeneity and the lack of association 
between prognosis and specific mutations. Among those tested, approximately 35% is found 
to be positive for a known gene.2021 Yield of genetic testing is even lower in elderly patients 
with HCM, and approaches 10% in those with sigmoidal HCM (figure 2).2334 Recently, two 
large HCM studies confirmed that a younger age at diagnosis and a reverse curve HCM were 
the principal predictors of mutation-positive HCM.2021 Thus, genetic testing is currently not 
part of the routine assessment of patients with suspected HCM, particularly at older ages, as 
a final diagnosis of HCM primarily relies on the clinical phenotype.
Considering the very low probability of a patient with sigmoidal HCM being gene positive 
for a known HCM-related mutation, genetics has not been consistently studied in patients 
with VSB, and it seems of no help in the discrimination between the two conditions. 
European HCM guidelines states that ‘advice on family screening in this group is 
challenging, but should be guided by the implications for family members and the presence 
of suspicious symptoms in relatives’.10 As the cost of genetic testing is expected to decrease 
in the coming years, widespread genotyping of elderly patients with HCM and VSB might 
be considered in the future and lead to the identification of pathological phenotypes and new 
HCM-causative mutations, which could potentially serve for the early diagnosis of HCM in 
younger family members.
HISTOLOGY
Histology remains the cornerstone for the diagnosis of HCM. Pathological hallmarks include 
myocyte hypertrophy and disarray. Myocyte disarray is found less frequently in bioptic 
specimens of older versus younger patients with HCM undergoing subaortic septal 
myectomy,47 and it is absent or less relevant in other conditions, which macroscopically may 
simulate HCM, such as hypertensive heart disease and aortic stenosis.48 There are no 
pathology data of VSB populations in the literature. Although myocyte disarray could 
potentially help differentiating true HCM from VSB in elderly patients, current guidelines 
do not recommend endomyocardial biopsy as part of the routine HCM diagnostic work-up.
10 Emerging imaging techniques that allow virtual histology may offer non-invasive 
alternatives for the assessment of myocardial disarray in the future.
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PROPOSAL FOR A DIFFERENTIAL DIAGNOSTIC ALGORITHM
Our review of the available literature demonstrates a considerable overlap between VSB and 
HCM in elderly individuals, and the lack of distinctive diagnostic features. In an attempt to 
keep considering the two as separate phenotypes, a differential diagnostic flowchart based 
on evidence discussed in this review is proposed in figure 4. Family history, clinical 
presentation and echocardiographic measurements may be leveraged to adjudicate on a 
particular patient, with several cases falling into the ‘grey zone’ of uncertainty, and 
potentially candidates for more advanced and invasive diagnostics, including CMR, genetic 
testing and endomyocardial biopsy. However, distinguishing between HCM and VSB 
remains a clinical challenge and a topic of intense debate, and the question on whether or not 
VSB exists as a separate disease entity with different natural history and prognosis has to 
date no definite answer. Further research and clinical studies are warranted to develop 
superior diagnostic approaches capable of identifying elderly individuals who would deserve 
further clinical attention.
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Box 1 Definitions, search strategy and selection criteria
Definitions
► Hypertrophic cardiomyopathy: according to the most recent European and 
American guidelines, hypertrophic cardiomyopathy (HCM) is defined by the 
presence of a wall thickness ≥15 mm in one or more left ventricular 
myocardial segments that is not solely explained by abnormal loading 
conditions.1011
► Ventricular septal bulge: a unique definition and specific diagnostic criteria 
are not established.10 Studies generally include individuals with an isolated 
basal septal hypertrophy and a wall thickness >12–13 mm; sometimes a 
proximal-to-mid/distal septal wall thickness ratio ≥1.3–1.5 is used as an 
additional criterion, and the presence of left ventricular outflow tract 
obstruction as an exclusion criterion, because considered diagnostic for 
HCM. The phenotype has been variously labelled ventricular septal bulge 
(VSB),1–3 sigmoid-shaped septum,12 localised 4513 or isolated 14 or discrete 
upper or basal septal hypertrophy.1516 Detailed definitions of VSB in each 
study are presented in online supplementary table S1. A case study is given in 
figure 1.
Search strategy
► PubMed and Embase were searched for articles in English and published 
before December 2014 by using the terms ‘hypertrophic cardiomyopathy’, 
‘elderly’, ‘older adults’, ‘septal bulge’, ‘sigmoid septum’, ‘septal 
hypertrophy’ and ‘senile heart’, with filters.
Selection criteria
► This review is focused on elderly individuals, thus only case reports and 
studies of individuals ≥60 years of age were considered. A summary of main 
findings from each study is presented in online supplementary table S1.
► Studies of discrete subvalvar aortic stenosis, which instead is a fixed stenosis 
caused by a fibrous ridge in the left ventricular outflow tract just proximal to 
the aortic valve, were excluded, as well as studies of patients with aortic 
stenosis. Asymmetric pattern of wall thickening is found in about 20%–30% 
of patients with aortic stenosis;17 however, they are routinely excluded from 
both HCM and VSB studies, and probably represent a different entity.
Canepa et al. Page 13














Representative image illustrating measurement of isolated basal septal hypertrophy. Two-
dimensional echocardiographic parasternal long-axis view from a 71-year-old male who met 
all the criteria for ventricular septal bulge (A). The maximal thickness of the proximal 
septum (measured within the first third of the septal length, usually within 20 mm from the 
insertion of the right aortic cusp) was 17 mm, which was approximately twice the thickness 
of the mid septum (usually measured at the second third of the septal length), measuring 8 
mm. Note that the very proximal fibrous part of the septum should be discarded (B, dashed 
line). From the same parasternal view, the thickness of the posterior wall is usually 
measured, which could help in the differential diagnosis between ventricular septal bulge 
and hypertrophic cardiomyopathy (see the text and figure 3 for details, and the 
corresponding movie in the online supplementary data).
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Patterns of left ventricular hypertrophy observed in patients with hypertrophic 
cardiomyopathy (HCM). The figure shows the most common septal morphologies in HCM. 
The table under the figure indicates estimates of the overall prevalence, the age at onset and 
the yield of genetic testing for each pattern. Modified from Bos et al,32 Binder et al 34 and 
Lever et al.25
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Main echocardiographic features that could help in distinguishing between HCM and VSB 
in elderly patients. Ao, aorta; HCM, hypertrophic cardiomyopathy; IVS, interventricular 
septum; LA, left atrium; LV, left ventricle; LVOTPG, left ventricular outflow track pressure 
gradients; PW, posterior wall; SAM, systolic anterior movement of the mitral valve; VSB, 
ventricular septal bulge.
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Differential diagnostic algorithm of elderly individuals with an isolated proximal septal 
hypertrophy. An individual enters the differential diagnostic algorithm only if both the ‘entry 
criteria’ are met; subsequently, a diagnosis of HCM or VSB is established only if all (or 
most of) the ‘principal criteria’ are present or absent, respectively. In uncertain ‘grey’ cases, 
in which some principal criteria are present but other are absent, and a definitive diagnosis is 
sought, ‘further criteria’ involving CMR, genetic testing and endomyocardial biopsy may be 
considered. CMR, cardiovascular MR; HCM, hypertrophic cardiomyopathy; IVS, 
interventricular septum; LVOT, left ventricular outflow tract; PW, posterior wall; SAM, 
systolic anterior movement of the mitral valve; SCD, sudden cardiac death; VSB, ventricular 
septal bulge.
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Table 1
Occurrence at diagnosis of selected clinical and instrumental features in elderly individuals with isolated basal 
septal hypertrophy
HCM VSB Notes
1. Demographics and medical history
 Diagnosis at age ≥60 years ++ +++ Few data available on the prevalence of HCM in the elderly
 Female predominance + – Reversed female predominance only in patients with HCM ≥60 years
 Family history of HCM/SCD ++ – Few negative data available from VSB studies
 History of hypertension + ++ Different criteria for diagnosis in HCM and VSB studies
2. Symptoms and physical examination
 Chest pain, dyspnoea or syncope +++ + VSB diagnosed retrospectively, few case reports with symptoms
 Dynamic systolic murmur + NA Poorly investigated and reported in contemporary populations
3. Electrocardiography
 LVH (rest ECG) ++ + Different criteria for diagnosis in HCM and VSB studies
 Arrhythmias (ambulatory ECG) ++ NA Recommended in patients with HCM to assess risk of SCD and stroke
4. Echocardiography
 Sigmoidal septum +++ +++ This is the main imaging feature that equates the two conditions
 IVS diastolic thickness ≥15 mm +++ – Thicker IVS in HCM than VSB studies
 PW diastolic thickness >11 mm +++ – Thicker PW in HCM than VSB studies
 Sharp aortoseptal angle + ++ Little reproducible measurements by echo, only few CMR studies
 Mitral annulus calcification ++ ++ Different criteria for diagnosis in HCM and VSB studies
 LVOT obstruction and SAM +++ + No prospective VSB study with stress echocardiography
 LV diastolic dysfunction ++ + Doppler data not available from older HCM and VSB studies
5. Cardiovascular MR
 LV mass and LVH patterns + NA Few data in elderly patients with HCM and no data in patients with VSB
 Mitral valve abnormalities + NA Few data in elderly patients with HCM and no data in patients with VSB
 Late gadolinium enhancement + NA Few data in elderly patients with HCM and no data in patients with VSB
6. Coronary angiography
 Coronary artery disease + + Potential link between RCA/LCX stenosis and sigmoidal LVH
7. Genetics
 Prevalence of known mutations + NA Very low yield of genetic testing in elderly patients with HCM
8. Histology
 Myocyte disarray ++ NA Biopsy not recommended in routine HCM diagnostic work-up
CMR, cardiovascular MR; HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LCX, left circumflex coronary artery; LV, left 
ventricular; LVH, left ventricular hypertrophy; LVOT, left ventricular outflow tract; NA, no evidences available; PW, posterior wall; RCA, right 
coronary artery; SAM, systolic anterior movement of the mitral valve; SCD, sudden cardiac death; VSB, ventricular septal bulge; −, negative 
evidences available; + to +++, from few to plenty of evidences available, arbitrary scale.
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